176 related articles for article (PubMed ID: 25481051)
21. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
[TBL] [Abstract][Full Text] [Related]
22. Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines.
Baek KH
Am J Hematol; 2002 Dec; 71(4):340-5. PubMed ID: 12447969
[TBL] [Abstract][Full Text] [Related]
23. Deubiquitinating enzymes in cellular signaling and disease regulation.
Hanpude P; Bhattacharya S; Dey AK; Maiti TK
IUBMB Life; 2015 Jul; 67(7):544-55. PubMed ID: 26178252
[TBL] [Abstract][Full Text] [Related]
24. Perspectives of CD44 targeting therapies.
Orian-Rousseau V; Ponta H
Arch Toxicol; 2015 Jan; 89(1):3-14. PubMed ID: 25472903
[TBL] [Abstract][Full Text] [Related]
25. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways.
Slevin M; Krupinski J; Gaffney J; Matou S; West D; Delisser H; Savani RC; Kumar S
Matrix Biol; 2007 Jan; 26(1):58-68. PubMed ID: 17055233
[TBL] [Abstract][Full Text] [Related]
26. Involvement of hyaluronan and its receptor CD44 with choroidal neovascularization.
Mochimaru H; Takahashi E; Tsukamoto N; Miyazaki J; Yaguchi T; Koto T; Kurihara T; Noda K; Ozawa Y; Ishimoto T; Kawakami Y; Tanihara H; Saya H; Ishida S; Tsubota K
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4410-5. PubMed ID: 19339747
[TBL] [Abstract][Full Text] [Related]
27. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
Pal A; Young MA; Donato NJ
Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
[TBL] [Abstract][Full Text] [Related]
28. Cationic conjugated polymer/fluoresceinamine-hyaluronan complex for sensitive fluorescence detection of CD44 and tumor-targeted cell imaging.
Huang Y; Yao X; Zhang R; Ouyang L; Jiang R; Liu X; Song C; Zhang G; Fan Q; Wang L; Huang W
ACS Appl Mater Interfaces; 2014; 6(21):19144-53. PubMed ID: 25278260
[TBL] [Abstract][Full Text] [Related]
29. Cytokine induction of the ability of human monocyte CD44 to bind hyaluronan is mediated primarily by TNF-alpha and is inhibited by IL-4 and IL-13.
Levesque MC; Haynes BF
J Immunol; 1997 Dec; 159(12):6184-94. PubMed ID: 9550421
[TBL] [Abstract][Full Text] [Related]
30. Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?
Poondla N; Chandrasekaran AP; Kim KS; Ramakrishna S
BMB Rep; 2019 Mar; 52(3):181-189. PubMed ID: 30760385
[TBL] [Abstract][Full Text] [Related]
31. Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication.
He M; Zhou Z; Wu G; Chen Q; Wan Y
Pharmacol Ther; 2017 Sep; 177():96-107. PubMed ID: 28279784
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathways: translational potential of deubiquitinases as drug targets.
D'Arcy P; Linder S
Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788
[TBL] [Abstract][Full Text] [Related]
33. Regulatory interplay between deubiquitinating enzymes and cytokines.
Woo B; Baek KH
Cytokine Growth Factor Rev; 2019 Aug; 48():40-51. PubMed ID: 31208841
[TBL] [Abstract][Full Text] [Related]
34. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective.
Götte M; Yip GW
Cancer Res; 2006 Nov; 66(21):10233-7. PubMed ID: 17079438
[TBL] [Abstract][Full Text] [Related]
35. Putative role of SUMOylation in controlling the activity of deubiquitinating enzymes in cancer.
Masoumi KC; Marfany G; Wu Y; Massoumi R
Future Oncol; 2016 Feb; 12(4):565-74. PubMed ID: 26777062
[TBL] [Abstract][Full Text] [Related]
36. Measurement of deubiquitinating enzyme activity via a suicidal HA-Ub-VS probe.
Rivard C; Bazzaro M
Methods Mol Biol; 2015; 1249():193-200. PubMed ID: 25348307
[TBL] [Abstract][Full Text] [Related]
37. Hyaluronan: towards novel anti-cancer therapeutics.
Karbownik MS; Nowak JZ
Pharmacol Rep; 2013; 65(5):1056-74. PubMed ID: 24399703
[TBL] [Abstract][Full Text] [Related]
38. Hyaluronan and CD44: modulators of chondrocyte metabolism.
Knudson CB; Knudson W
Clin Orthop Relat Res; 2004 Oct; (427 Suppl):S152-62. PubMed ID: 15480059
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes.
Cruz L; Soares P; Correia M
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577547
[TBL] [Abstract][Full Text] [Related]
40. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44.
Quan YH; Kim B; Park JH; Choi Y; Choi YH; Kim HK
Exp Lung Res; 2014 Dec; 40(10):475-84. PubMed ID: 25299431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
